Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2022 07:00 ET | Source: Humacyte, Inc

Humacyte Human Acellular Vessel™ (HAV™) Ukraine Humanitarian Results to be Presented at Multiple Vascular Conferences in December 2022

DURHAM, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and...
November 23, 2022 08:00 ET | Source: Humacyte, Inc

Humacyte to Present at the 34th Annual Piper Sandler Healthcare Conference

DURHAM, N.C., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...
November 10, 2022 07:00 ET | Source: Humacyte, Inc

Humacyte Third Quarter 2022 Financial Results and Business Update

-- Progress Continues in Clinical Development of Human Acellular Vessel™ (HAV™) for Vascular Trauma; BLA Filing Anticipated mid 2023 – -- Experience with HAV in Ukrainian War Vascular Trauma Mirrors...
November 07, 2022 08:00 ET | Source: Humacyte, Inc

Humacyte Presents Six-Month Human Acellular Vessel™ (HAV™) Coronary Artery Bypass Graft (CABG) Data at the American Heart Association Scientific Sessions 2022 Meeting

Six-month primate HAV CABG model demonstrates patency, recellularization and remodeling resembling native blood vessels HAV may address many limitations of current standard of care grafts used in...
November 03, 2022 08:00 ET | Source: Humacyte, Inc

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 10, 2022

DURHAM, N.C., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue, complex...
September 23, 2022 08:00 ET | Source: Humacyte, Inc

Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual Meeting

DURHAM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues,...
September 20, 2022 08:00 ET | Source: Humacyte, Inc

Humacyte Expands Board of Directors and Leadership Team with New Appointments

Lt. General Bruce Green, M.D., USAF-ret. Joins Board of Directors Cindy Cao, Ph.D. Appointed as Chief Regulatory Officer DURHAM, N.C., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc....
September 09, 2022 08:00 ET | Source: Humacyte, Inc

Humacyte Announces Presentation on Investigational Human Acellular VesselTM for Treatment of Vascular Trauma at the International Committee of Military Medicine World Congress

DURHAM, N.C., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues,...
September 08, 2022 08:01 ET | Source: Humacyte, Inc

Humacyte Presents at Multiple Conferences in September 2022

DURHAM, N.C., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and...
August 12, 2022 07:00 ET | Source: Humacyte, Inc

Humacyte Second Quarter 2022 Financial Results and Business Update

-- Human Acellular Vessels™ (HAVs™) successfully implanted in wounded Ukrainian citizens and reported to be functioning, saving limbs – -- Hosted key opinion leader (KOL) webinar on HAV in the...